Pediatric Oncology

AML

Questions discussed in this category

How do you approach an isolated CNS relapse of AML in a young child under the age of 5?

What is the preferred treatment regimen for an adolescent or young adult patient with treatment-related AML?

What is the current opinion on G-CSF usage for AML patients during induction and consolidation phases of treatment?

It used to be a contraindication for G-CSF use for AML patients, but currently, several protocols include it to decrease neutropenic duration.

1 Answer available

Is there data to support holding the 5th cycle of intensification for an AML patient with good prognosis and a history of significant infections and/or prolonged count recovery?

1 Answer available

Is a patient with secondary myeloid sarcoma a candidate for hematopoietic stem cell transplant?

2 Answers available

Is there a utility to initiating maintenance azacitidine therapy for a patient with a history of refractory AML who is now post-transplant?

1 Answer available

What therapy would you give to an AML patient with induction failure while awaiting HSCT?

Patient treated per AAML0531

1 Answer available

What are the treatment options available for isolated extramedullary relapse of an AYA patient with AML following HSCT?

Particular patient is s/p 2 HSCTs

1 Answer available

What are the current frontline treatment options for newly diagnosed pediatric AML patients with high FLT3/ITD allelic ratio and IDH2 mutation?

1 Answer available

Would you use a myeloablative or reduced intensity conditioning regiment for a pediatric or AYA patient who does not recover their counts after treatment for AML, but remains disease free?

Would you test for bone marrow failure syndromes before beginning the conditioning regimen?

1 Answer available

With the increased use of gemtuzumab in induction chemotherapy for children with acute myeloid leukemia, would you change conditioning regimens to help prevent sinusoidal obstruction syndrome during hematopoietic stem cell transplant?

Or do you use prophylactic defibrotide?

2 Answers available

At what level of bone marrow disease would you agree to proceed with transplant for a patient with refractory AML?

I have heard <20% MRD. What about proceeding if patient is hypoplastic after chemotherapy?

1 Answer available

How do you treat pediatric AML that has relapsed after transplant?

Should the goal always be to proceed to a second transplant?

1 Answer available

How would you approach treatment in an otherwise young, fit patient with transformed AML currently in remission with a plan for transplant and was found to have an invasive fungal infection not amenable to resection upon recovery from induction?

Would you consider “bridging” therapy with something like an HMA?

1 Answer available

What are the options of induction treatment of young AML patients who are on CRRT, continuous renal replacement therapy ?

1 Answer available

For pre-menopausal female patients who present with acute leukemia in need of urgent anti-neoplastic therapy, what is your preferred approach in effort to preserve fertility?

Does acute leukemia sub-type affect your decision?

1 Answer available

What treatment do you offer to a pediatric patient with AML in first relapse who was previously treated with chemotherapy only (not transplanted)?

1 Answer available

Papers discussed in this category

Fertil. Steril., 2013 Sep 05

Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion.

Pediatric blood & cancer, 2014-03

Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia.

Clin Lymphoma Myeloma Leuk, 2017 Mar 07

Myeloid Sarcoma: Presentation, Diagnosis, and Treatment.

J Clin Oncol, 2020 May 13

Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group.

American journal of hematology, 2019-07

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia.

Pediatr Blood Cancer, 2018 Jun 12

Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia.

British journal of haematology, 2011-11

Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial.

Haematologica, 2020 Feb 6

Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group.

Blood, 2013-05-02

Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group.

Cochrane Database Syst Rev, 2012 Jun 13

Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia.

N Engl J Med,

Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.

Blood, 2006 Sep 28

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia.

J Clin Oncol, 2010 Apr 20

Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse.

J Clin Oncol,

Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005-12-20

Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia.

Pediatric Oncology

AML

Questions discussed in this category

Papers discussed in this category

Related Topics in Pediatric Oncology